Markus Hecker

Corporate Officer/Principal at Ruprecht-Karls-Universität Heidelberg

Consumer Services

Health Technology

Markus Hecker active positions

Companies	Position	Start	End
Ruprecht-Karls-Universität Heidelberg	Corporate Officer/Principal	2009-11-04	-
Ruprecht-Karls-Universität Heidelberg	Director/Board Member	-	2009-11-04

Companies	Position	Start	End
Avontec GmbH Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.	Director/Board Member	2001-07-31	2010-06-15
	Founder	2009-11-04	2010-06-15
University of Gottingen	Corporate Officer/Principal	1995-12-31	2003-12-31
University of Freiburg	Corporate Officer/Principal	-	-
St. Bartholomew's Hospital	Corporate Officer/Principal	-	-
Georgetown University	Corporate Officer/Principal	-	-

Universität Konstanz

Doctorate Degree

International

Operational

Corporate Officer/Principal	5
Director/Board Member	2
Founder	1

Sectoral

Consumer Services	6
Health Technology	2

Positions held

Active

Inactive

Listed companies

Private companies

Private companies	2
Avontec GmbH Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development.	Health Technology
St. Bartholomew's Hospital

Private companies

Health Technology

St. Bartholomew's Hospital